Mesothelin/MSLN Proteins, Antibodies and Stable Cell Lines

Mesothelin (MSLN) is a tumor-associated cell-surface glycoprotein synthesized as a precursor that undergoes proteolytic processing to generate a soluble N-terminal megakaryocyte potentiating factor and a mature GPI-anchored membrane-associated Mesothelin protein. In healthy adults, Mesothelin expression is largely restricted to mesothelial cells lining the pleura, peritoneum, and pericardium. In contrast, elevated cell-surface expression is found in mesothelioma and multiple epithelial malignancies. Its relatively restricted normal-tissue distribution, high tumor-associated expression, and antibody-mediated internalization have made Mesothelin a prominent target for monoclonal antibodies, ADCs, T-cell engagers, multispecific molecules, and engineered cell therapies.

DIMA BIOTECH provides human and cynomolgus Mesothelin recombinant proteins in multiple formats for ELISA, antibody screening, SPR/BLI, affinity characterization, and cross-species evaluation. Rabbit monoclonal antibodies validated by ELISA, flow cytometry, and selected IHC assays are complemented by reference antibodies and PE/biotin-conjugated formats for cell-surface detection and candidate benchmarking. A Mesothelin-overexpressing stable cell line provides an additional platform for FACS, cell-binding, internalization, and functional candidate screening. DIMA also maintains Mesothelin lead-antibody resources that can be advanced into humanization, affinity maturation, and downstream functional evaluation.